Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President

Chugai President and CEO Osamu Okuda Chugai Pharmaceutical is currently focusing on the Japan development of three COVID-19 treatment candidates - antibody cocktail therapy, immunomodulator Actemra (tocilizumab), and novel oral therapy AT-527, President and CEO Osamu Okuda said on May...read more